Dashboard
Manage Tickers

OPK OPKO HEALTH, INC.

Nasdaq opko.com


$ 1.46 $ 0.00 (0 %)    

Tuesday, 28-Oct-2025 07:00:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.30 $ 0.00 (0 %)
DIA $ 477.46 $ 0.00 (0 %)
SPY $ 685.99 $ 0.00 (0 %)
TLT $ 91.89 $ 0.00 (0 %)
GLD $ 361.30 $ 0.00 (0 %)
$ 1.45
$ 1.50
$ 1.44 x 2,474
$ 1.46 x 2,242
-- - --
$ 1.11 - $ 2.04
1,272,493
na
1.15B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 02-18-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

an-opko-healths-modex-therapeutics-company-doses-first-patient-in-its-phase-12a-trial-of-mdx2004-a-first-in-class-trispecific-antibody-fusion-protein-for-advanced-cancers
An OPKO Health's Modex Therapeutics Compan...
10/28/2025 12:08:26

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstra...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

opko-health-q2-adj-eps-007-beats-011-estimate-sales-156800m-miss-165744m-estimate
OPKO Health Q2 Adj. EPS $(0.07) Beats $(0....
07/31/2025 20:11:07

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

Core News & Articles
OPKO Health And Entera Bio To Present Abst...
07/08/2025 12:09:42

Core News & Articles
NextPlat Interim CEO Issues Shareholder L...
06/30/2025 12:08:30

NextPlat Corp (NASDAQ:NXPL, NXPLW)), NXPLW) ("NextPlat" or the "Company"), a global consumer products and servi...

Core News & Articles
OPKO Health And Entera Bio Say New Pharmac...
06/25/2025 12:12:35

OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and ...

opko-healths-modex-therapeutics-forms-scientific-advisory-board-to-guide-development-of-next-gen-multispecific-antibodies-for-cancer-and-immune-diseases
OPKO Health's ModeX Therapeutics Forms Sci...
06/09/2025 12:39:36

Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving ...

barrington-research-maintains-outperform-on-opko-health-maintains-225-price-target
Barrington Research Maintains Outperform o...
05/01/2025 18:20:21

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform and maintains $2.25 price t...

opko-health-q1-eps-010-misses-007-estimate-sales-14990m-miss-16426m-estimate
OPKO Health Q1 EPS $(0.10) Misses $(0.07) ...
04/30/2025 20:20:01

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) ...

Core News & Articles
Earnings Scheduled For April 30, 2025
04/30/2025 08:32:41

analyst-expectations-for-opko-healths-future
Analyst Expectations For OPKO Health's Future
04/25/2025 19:00:18

Core News & Articles
This Rocket Lab Analyst Begins Coverage On...
04/25/2025 13:56:22

jp-morgan-initiates-coverage-on-opko-health-with-neutral-rating
JP Morgan Initiates Coverage On OPKO Healt...
04/25/2025 10:41:33

JP Morgan analyst Eric Joseph initiates coverage on OPKO Health (NASDAQ:OPK) with a Neutral rating.

opko-health-stock-a-deep-dive-into-analyst-perspectives-7-ratings
OPKO Health Stock: A Deep Dive Into Analys...
04/07/2025 18:00:48

hc-wainwright--co-reiterates-buy-on-opko-health-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on OPKO...
04/07/2025 16:57:02

HC Wainwright & Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:OPK) with a Buy and maintains $3 price target.

opko-health-announces-100m-increase-to-its-existing-share-repurchase-program-bringing-the-aggregate-capacity-of-the-program-to-200m
OPKO Health Announces $100M Increase To It...
04/04/2025 12:05:35

OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the C...

forecasting-the-future-6-analyst-projections-for-opko-health
Forecasting The Future: 6 Analyst Projecti...
03/19/2025 12:00:29

hc-wainwright--co-reiterates-buy-on-opko-health-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on OPKO...
03/19/2025 11:11:04

HC Wainwright & Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:OPK) with a Buy and maintains $3 price target.

Core News & Articles
OPKO Health And Entera Bio Enter Collabora...
03/17/2025 12:02:13

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION